08 immunology

+Immune Pharmacology Shan Nanji

+Immuno Pharmacology

nCyclosporine n Binds to __________________ n Inhibits __________________which prevents production

of I __________________and its receptor.

Shan Nanji - [email protected]

2


nTacrolimus TacrolimBBus n Aka FK506

n Inhibits __________________ S/E: n Nephrotoxicity n __________________ n __________________ n Hyperglycemia n __________________


3


nSirolimus SEEroLIMus n Aka Rapamycin n __________________ n Limits __________________ proliferation

S/E n __________________ n Thrombocytopenia n Leukopenia


4


nDaclizumab DA-Klizumab n Antibody against __________________ n Clinical Use:

n DA-Kidney Transplants


5


nAzathioprine n Antimetabolite precursor __________________ that interferes

with metabolism and synthesis of nucleic acids.

nClinical Use: n Kidney Transplantation

n __________________ S/E: n __________________, active metabolite Mercaptopurine

is metabolized by Xanthine Oxidase n Toxic effects increased on __________________.


6


nMuromonab Morononab n Monocolonal AB that binds to __________________ on the

surface of T-Cells - __________________

n __________________ n Clinical Use:

n Immunosuppression after Kidney Transplantation

S/E: n Cytokine Release Syndrome n Hypersensitivty


7


nTrastuzumab/Herceptin TRUSTuzumab n Target: erb-B2 n Clinical Use:

n Her-2 overexpressing Breast Cancer n DONT TRUST HER


8


nRituximab n Target: CD20 n Clinical Use:

n __________________


9


nInfliximab INFL-iximab n Target: __________________ n Clinical Use:

n Crohns Disease n Rheumatoid Arthritis n Psoriatic Arthritis n Ankylosing Spondylitis


10


nAdalimumab n Target: TNF-Alpha n Clinical Use:

n Crohns Disease n Rheumatoid Arthritis n Psoriatic Arthritis


11


nEtanercept n Target: __________________ n Clinical Use:

n Crohns Disease n Rheumatoid Arthritis n Psoriatic Arthritis


12


nDigoxin Immune Fab n Target: Digoxin n Clinical Use:

n Digoxin poisoning


13


nAbciximab n Target: __________________ n Clinical Use:

Prevents Cardiac Ischemia in: n Unstable Angina n Percutaneous Coronary Intervention Patients n Current Myocardial Infarction Patients


14


nOmalizumab n Target __________________ n Clinical Use:

n Treatment option for __________________


15


nMycophenolate n Target __________________Prevents Production of the

Nucleoside Guanine n Leads to rapid arrest of B/T cell proliferation

n Clinical Use: n Transplants

n __________________


16


nThalidomide (AKA Contergan) n Target: __________________ n Clinical Use:

n Immunosupression:

n __________________ n Organ Transplants

n Anti-Angiogenic


17


nThalidomide (AKA Contergan) nS/E: n __________________ (fetal development problems)

n Underdeveloped/malformed limbs and bones n Encephalocele n Hydrocephalus

n Leads to Vomiting and Migraines n Bicornate Uterus n Heart and Kidney Malformations n Urethral Abnormalities n Short Stature


18


nAldesleukin nInterleukin-2 Recombinant Cytokine n Clinical Use:

n Renal Cell Carcinoma n Metastatic Melanoma


19


nErythropoietin nEpoetin Recombinant Cytokine n Clinical Use:

n Anemias n In Renal Failure Especially Due to

EPO not being produced


20


nFilgrastim FilGRA STIM n________________________________

nIL-___ n Clinical Use:

n _____________________


21


nSargramostim SarGRA MoSTIM n _____________________ n IL-3

n Clinical Use: n _____________________


22


n-Interferon n Recombinant Cytokine

nClinical Use: n _____________________ n Kaposis Sarcoma n _____________________ n Malignant Melanoma


23



nClinical Use: n _____________________


24



nClinical Use: n _____________________

n Aids Phagocytes


25


nOprelvekin n _____________________ Recombinant Cytokine

nClinical Use: nThrombocytopenia


26


nThrombopoietin n Recombinant Cytokine

nClinical Use: nThrombocytopenia


27

08 immunology

Documents

n transplants n

n nephrotoxicity n

n hyperglycemia n

n kidney transplantation

n digoxin

n immunosuppression

n limits

proliferation se n